Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose intravenous melphalan: a review

B L Samuels1, J D Bitran

  • 1Department of Medicine, Lutheran General Hospital, University of Chicago School of Medicine, Park Ridge, IL, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|July 1, 1995
PubMed
Summary

High-dose melphalan (HDM) shows significant clinical activity in relapsed cancers like myeloma and neuroblastoma. Its favorable toxicity profile and availability of progenitor cells allow for repeated treatments, establishing it as an effective salvage and consolidative therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous Bone Marrow Transplantation Followed by Involved Field Radiotherapy in Patients with Relapsed or Refractory Hodgkin's Disease.

Leukemia & lymphoma·2016
Same author

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.

British journal of cancer·2012
Same author

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

Bone marrow transplantation·2010
Same author

Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial.

Journal of chemotherapy (Florence, Italy)·2009
Same author

Allogeneic hematopoietic cell transplantation for metastatic breast cancer.

Bone marrow transplantation·2007

Area of Science:

  • Pharmacology and clinical trials
  • Oncology and hematology

Background:

  • Intravenous high-dose melphalan (HDM) is a chemotherapy agent.
  • Autologous bone marrow support (ABMS) or peripheral-blood progenitor cells (PBPCs) are used with HDM.

Purpose of the Study:

  • To review the clinical pharmacology of HDM.
  • To review clinical trials that have used HDM.

Main Methods:

  • Reviewed mechanism of action, clinical pharmacology, and clinical studies of HDM.
  • Included studies in myeloma, ovarian cancer, lymphoma, breast cancer, neuroblastoma, Ewing's sarcoma, and acute leukemia.
  • Considered HDM with and without ABMS or PBPCs.

Main Results:

  • HDM exhibits a short distribution half-life (5-15 min) and elimination half-life (17-75 min) with significant variability.

Related Experiment Videos

  • Demonstrated clinical activity in relapsed multiple myeloma, ovarian cancer, Hodgkin's disease, breast cancer, and neuroblastoma.
  • Toxicities include myelosuppression, nausea, vomiting, mucositis, diarrhea, and hepatic veno-occlusive disease.

    • Conclusions:

    • HDM is an established salvage regimen for relapsed neuroblastoma and consolidative treatment for high-risk neuroblastoma.
    • HDM is emerging as an effective treatment for stage II and III myeloma.
    • Favorable toxicity and PBPC availability permit repetitive HDM therapy.